DOI
stands for Digital Object Identifier
（
D
igital
O
bject
I
dentifier
）
,
and is the unique identifier for objects on the internet. It can be used to create persistent link and to cite articles.
Using DOI as a persistent link
To create a persistent link, add「http://dx.doi.org/」
「
http://dx.doi.org/
」
before a DOI.
For instance, if the DOI of an article is
10.5297/ser.1201.002
, you can link persistently to the article by entering the following link in your browser:
http://dx.doi.org/
10.5297/ser.1201.002
。
The DOI link will always direct you to the most updated article page no matter how the publisher changes the document's position, avoiding errors when engaging in important research.
Cite a document with DOI
When citing references, you should also cite the DOI if the article has one. If your citation guideline does not include DOIs, you may cite the DOI link.
DOIs allow accurate citations, improve academic contents connections, and allow users to gain better experience across different platforms. Currently, there are more than 70 million DOIs registered for academic contents. If you want to understand more about DOI, please visit airiti DOI Registration （ doi.airiti.com ） 。
Export
Track
Add to Cart
E-mail To Friend
Print Bibliography
Report an Issue
Purchase Single Articles
Download PDF
建立篩選第二型糖尿病新治療藥物-選擇性SGLT2抑制劑-之細胞平台
楊書阜 , Masters Advisor：許麗卿
繁體中文
DOI：
10.6342/NTU.2010.01138
第二型糖尿病 ； 鈉離子依賴型葡萄糖運輸蛋白 ； Phlorizin ； Dapagliflozin ； Type II diabetes (T2DM) ； sodium dependent glucose cotransporter ； Dapagliflozin ； Phlorizin
- 1. Rathmann, W. and G. Giani, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004.27(10),2568.
連結：
- 2. Chiang, C.W.,Chen,C. Y.,Chiu,H.F.,Wu,H.L.,Yang,C.Y., Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf, 2007.16(4),412.
連結： - 5. Campbell, R.K., Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc (2003),2009.49,S3. 6. Guilherme, A.,Virbasius,J.V.,Puri,V.,Czech, M. P., Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol, 2008.9(5), 367.
連結： - 7. Das, S.K. and R. Chakrabarti, Non-insulin dependent diabetes mellitus: present therapies and new drug targets. Mini Rev Med Chem, 2005. 5(11), 1019.
連結： - 8. Garg, S.K., The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther,2010.12(1),11.
連結：
